15:19 , Sep 14, 2018 |  BC Week In Review  |  Clinical News

CARsgen solid tumor CAR T leads to complete response

CARsgen Therapeutics Co. Ltd. (Shanghai, China) said its CAR-CLD18 T cell therapy led to five objective responses, including one complete response, in a pilot trial to treat relapsed or refractory gastric or pancreatic cancer. The...
19:45 , Sep 10, 2018 |  BC Extra  |  Clinical News

CARsgen solid tumor CAR T leads to complete response

CARsgen Therapeutics Co. Ltd. (Shanghai, China) said its CAR-CLD18 T cell therapy led to five objective responses, including one complete response, in a pilot trial to treat relapsed or refractory gastric or pancreatic cancer. The...
02:56 , May 4, 2018 |  BC Innovations  |  Targets & Mechanisms

Solid hopes for T cell bispecifics

As next-generation T cell bispecifics hit the clinic, demonstrating efficacy in solid tumors could earn them a place in the immuno-oncology tool kit alongside CAR T cells and checkpoint inhibitors. T cell bispecific antibodies bring activated...
20:42 , Oct 10, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Solid tumors Patient sample, cell culture, mouse and monkey studies suggest ERY974, a bispecific antibody against CD3 and GPC3, could help treat multiple types of GPC3-positive solid tumors. In tissue samples from patients with adenocarcinoma,...
22:45 , Oct 4, 2017 |  BC Extra  |  Preclinical News

Chugai team describes bispecific GPC3 antibody's efficacy

A study published Wednesday in Science Translational Medicine described a novel bispecific antibody that overcomes the "on-target, off-tumor" effects plaguing current cancer immunotherapies utilizing bispecific T-cell redirecting antibodies (TRAB). While the efficacy of current TRAB therapies...
19:55 , Jun 9, 2017 |  BC Week In Review  |  Clinical News

CARsgen reports Phase I data for anti-GPC3 CAR T in HCC

CARsgen Therapeutics Co. Ltd. (Shanghai, China) reported preliminary data from 5 evaluable patients with relapsed or refractory hepatocellular carcinoma (HCC) in a Chinese Phase I trial showing that CSG-GPC3 following lymphodepleting conditioning with fludarabine and...
02:14 , Jan 26, 2016 |  BC Extra  |  Financial News

Chinese CAR-T play CARsgen raises $30M

CARsgen Therapeutics Co. Ltd. (Shanghai, China) raised $30 million in a series B round led by KTB Ventures and Jolly Innovation Ventures. Kaitai Capital and JIC GenesisFountain Healthcare Ventures also participated. CARsgen is developing chimeric...
07:00 , Apr 9, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Glypican 3 (GPC3)

Cancer INDICATION: Liver cancer In vitro and mouse studies suggest a GPC3-targeting immunotoxin could help treat liver cancer. The immunotoxin consisted of a peptide fragment of a Pseudomonas exotoxin fused to an anti-GPC antibody that inhibited oncogenic...
08:00 , Dec 15, 2014 |  BioCentury  |  Finance

CAR T bet in China

BVCF typically invests in later-stage healthcare plays in China, but the PE firm's Zhi Yang said BVCF went out of its comfort zone by investing in a series A round in new cancer immunotherapy play...
08:00 , Nov 11, 2013 |  BioCentury  |  Strategy

New York translation

Now headquartered at the newly opened Translational Clinical Research Center in New York, Roche's Pharma Research & Early Development organization has undergone another retooling intended to increase its efficiency and productivity. The center will enable...